1de-la Rubia J, Regadera A, Moscardo F, et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF ) in the treatment of patients with high risk myeloid malignancies, leuk Res. 2002 , 26 :725 - 730.
2Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drug, 1994, 47 ( Suppl. 6 ) :30 - 38.
3Gandhi V, Estey E, Keating MJ, et al. fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol, 1993 , 11 : 116 - 124.
4Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de nove refractory anaemia with excess of blasts in transformation. Br J Haematol,2001 , 112 : 127 - 137.
5Carella AM, Cascavilla N, Greco MM, et al. Treatment of“Poorrisk” acute myeloid leukemia with fludarabine, cytarabine and GCSF (Flag Regimen ): a single center study. Leuk Lymphoma,2001 , 40:295 - 303.
6Vidarsson B, Abonour R, Williams EC, et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of aduhs with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma, 2001, 41:321 -331.
7Montillo M, Mirto S, Pierri MC, et al. fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol, 1998 , 58 : 105 - 109.
8Bohm A,Piribauer M,Wimazal F,et al.High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML:a single center experience[J].Leuk Res,2005,29(6):609-615.
9Jackson G,Taylor P,Smith GM,et al.A multicentre,open,non-comparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation[J].Br J Haematol,2001,112 (1):127-137.
10Hubeek I,Litvinova E,Peters GJ,et al.The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia[J].Int J Oncol,2004,25(6):1823-1829.
7THOMAS DA, KANTARJIAN HM, STOCK W, et al. Phase 1 muhicenter study of vincristine sulfate liposomes injec- tion and dexamethasone in adults with relapsed or refracto- ry acute lymphoblastic leukemia [ J ]. Cancer, 2009, 115 (23) : 5490 - 5498.
8CHOWDHURY S, SEROPIAN S, MARKS PW. et al. Decitabine combined with fractionated gemtuzumab ozo- gamicin therapy in patients with relapsed or refractory a- cute myeloid leukemia[ J]. Journal of Clinical Oncology, 2009,84 (9) :599 - 600.
9CHEVALLIER P, DELAUNAY J, TURLURE P, et al. Long- term disease -free survival after gemtuzumab, in- termediate -dose cytarabine, and mitoxantrone in patients with CD33 ( + ) primary resistant or relapsed acute mye- loid leukemia[ J]. Journal of Clinical Oncology, 2008, 26 (32) :5192 - 5197.
10HAROUSSEAU JL, LANCET JE, REIFFERS J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipif- arnib in patients with refractory or relapsed acute myeloid leukemia [ J ]. Blood,2007,109 (12) :5151 - 5156.
